The U.S. Patent and Trademark Office (USPTO) has announced a significant extension of the IP5 Patent Prosecution Highway (PPH) pilot ...

Pharmaceuticals underperformed the S&P 500 in 2023 but have been outperforming the broader market in 2024. The PPH fund offers exposure to pharmaceutical stocks and has outperformed its peers in terms ...

The VanEck Pharmaceutical ETF (NYSEARCA:PPH) has surged 26% over the past year, driven almost entirely by the weight-loss ...

“PPH requests appear to have been filed for less than 1% of U.S. applications. Why are applicants foregoing the program? While the program does not require payment of a fee per se, the author proposes ...

The VanEck Pharmaceutical ETF provides diversified exposure to the world's largest pharmaceutical companies, focusing on 'big pharma' through a cap-weighted index. PPH tracks the MVIS US Listed ...

Below is Validea's ETF fundamental report for VanEck Pharmaceutical ETF (PPH). The report looks at PPH's exposure to the major investing factors including value, quality, momentum and low volatility.

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.